Teva Relaunches Vecuronium Bromide for Injection

Vecuronium acts by competing for cholinergic receptors at the motor end-plate
Vecuronium acts by competing for cholinergic receptors at the motor end-plate

Teva announced the reintroduction and availability of Vecuronium Bromide for Injection, AP rated bioequivalent product.

Vecuronium Bromide for Injection, a non-depolarizing neuromuscular blocker, is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.  

Related Articles

Vecuronium acts by competing for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors (AChEI) such as neostigmine, edrophonium and pyridostigmine, can inhibit and reverse the neuromuscular block. The time to onset of paralysis decreases and the duration of maximum effect increases with higher vecuronium doses.

Vecuronium Bromide for Injection is available in a 10mg/vial strength intended for intravenous administration.

For more information call (888) 838-2872 or visit TevaGenerics.com.